189 related articles for article (PubMed ID: 26938643)
1. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of adverse events in patient receiving community-based therapy for multidrug-resistant tuberculosis in Pakistan.
Javaid A; Khan MA; Jan F; Rauf M; Khan MA; Basit A; Mehreen S
Tuberk Toraks; 2018 Mar; 66(1):16-25. PubMed ID: 30020037
[TBL] [Abstract][Full Text] [Related]
3. Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance.
Ahmad N; Javaid A; Basit A; Afridi AK; Khan MA; Ahmad I; Sulaiman SA; Khan AH
Int J Tuberc Lung Dis; 2015 Sep; 19(9):1109-14, i-ii. PubMed ID: 26260834
[TBL] [Abstract][Full Text] [Related]
4. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.
Atif M; Bashir A; Ahmad N; Fatima RK; Saba S; Scahill S
BMC Infect Dis; 2017 Sep; 17(1):655. PubMed ID: 28962599
[TBL] [Abstract][Full Text] [Related]
5. Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia.
Buziashvili M; Mirtskhulava V; Kipiani M; Blumberg HM; Baliashvili D; Magee MJ; Furin JJ; Tukvadze N; Kempker RR
Int J Tuberc Lung Dis; 2019 Sep; 23(9):1005-1011. PubMed ID: 31615608
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan.
Khan MA; Mehreen S; Basit A; Khan RA; Jan F; Ullah I; Ihtesham M; Khan A; Ullah U; Javaid A
Saudi Med J; 2015 Dec; 36(12):1463-71. PubMed ID: 26620989
[TBL] [Abstract][Full Text] [Related]
7. Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.
Rupani MP; Dave JD; Parmar VB; Singh MP; Parikh KD
Natl Med J India; 2020; 33(1):10-14. PubMed ID: 33565479
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan province of Pakistan.
Khan I; Ahmad N; Khan S; Muhammad S; Ahmad Khan S; Ahmad I; Khan A; Gulalai ; Atif M
J Infect Public Health; 2019; 12(6):809-815. PubMed ID: 31056438
[TBL] [Abstract][Full Text] [Related]
9. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
10. Adverse drug reactions in tuberculosis and management.
Prasad R; Singh A; Gupta N
Indian J Tuberc; 2019 Oct; 66(4):520-532. PubMed ID: 31813444
[TBL] [Abstract][Full Text] [Related]
11. Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam.
Ngoc NB; Vu Dinh H; Thuy NT; Quang DV; Huyen CTT; Hoa NM; Anh NH; Dat PT; Hoa NB; Tiemersma E; Nhung NV
PLoS One; 2021; 16(9):e0255357. PubMed ID: 34492031
[TBL] [Abstract][Full Text] [Related]
12. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.
Gualano G; Mencarini P; Musso M; Mosti S; Santangelo L; Murachelli S; Cannas A; Di Caro A; Navarra A; Goletti D; Girardi E; Palmieri F
PLoS One; 2019; 14(2):e0212948. PubMed ID: 30817779
[TBL] [Abstract][Full Text] [Related]
13. Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study.
Javaid A; Ullah I; Masud H; Basit A; Ahmad W; Butt ZA; Qasim M
Clin Microbiol Infect; 2018 Jun; 24(6):612-617. PubMed ID: 28970158
[TBL] [Abstract][Full Text] [Related]
14. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.
Bloss E; Kuksa L; Holtz TH; Riekstina V; Skripconoka V; Kammerer S; Leimane V
Int J Tuberc Lung Dis; 2010 Mar; 14(3):275-81. PubMed ID: 20132617
[TBL] [Abstract][Full Text] [Related]
15. Adverse drug reaction and its management in tuberculosis patients with multidrug resistance: a retrospective study.
Nilamsari WP; Rizqi MF; Regina NO; Wulaningrum PA; Fatmawati U
J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):783-787. PubMed ID: 34214373
[TBL] [Abstract][Full Text] [Related]
16. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa.
Schnippel K; Firnhaber C; Berhanu R; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Apr; 22(4):393-398. PubMed ID: 29562986
[TBL] [Abstract][Full Text] [Related]
17. Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment.
Kelly AM; Smith B; Luo Z; Given B; Wehrwein T; Master I; Farley JE
Int J Tuberc Lung Dis; 2016 Apr; 20(4):442-7. PubMed ID: 26970151
[TBL] [Abstract][Full Text] [Related]
18. Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis.
Prasad R; Singh A; Srivastava R; Hosmane GB; Kushwaha RA; Jain A
Indian J Tuberc; 2016 Apr; 63(2):106-14. PubMed ID: 27451820
[TBL] [Abstract][Full Text] [Related]
19. Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients.
Van der Walt M; Lancaster J; Odendaal R; Davis JG; Shean K; Farley J
PLoS One; 2013; 8(4):e58817. PubMed ID: 23573193
[TBL] [Abstract][Full Text] [Related]
20. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
